Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors

Table 1

Relationship between the expression of PD-L1 protein and clinicopathological features in TETs.

Clinicopathological factors	Case number	PD-L1 expression		Positive rate (%)		value
		+	−
Gender
Male	30	20	10	33.33	3.243	0.092
Female	40	18	22	45.00
Age
≤50 years	16	7	9	43.75	0.928	0.399
>50 years	54	31	23	57.41
Tumor size
≤4 cm	41	22	19	53.66	0.016	1.000
>4 cm	29	16	13	55.17
Histological classification
Type A	11	4	7	36.36	20.648	0.001
Type AB	13	2	11	15.39
Type B1	9	3	6	33.33
Type B2	7	6	1	85.71
Type B3	10	9	1	90.00
Type C thymic carcinoma	20	14	6	70.00
Masaoka-Koga staging
Stage I	32	10	22	31.25	12.402	0.004
Stage II	4	3	1	75.00
Stage III	20	15	5	75.00
Stage IV	14	10	4	71.42
With/without myasthenia gravis
Yes	11	7	4	63.64	0.460	0.533
No	59	31	28	52.54
Metastasis
Yes	14	10	4	71.43	2.072	0.231
No	56	28	28	50.00
Radiotherapy
Yes	37	26	11	70.27	8.081	0.008
No	33	12	21	36.36
Chemotherapy
Yes	21	16	5	76.19	5.800	0.02
No	49	22	27	44.90

.